{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:57:19Z","timestamp":1793159839891,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173835"],"award-info":[{"award-number":["82173835"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012242","name":"Program of Shanghai Subject Chief Scientist","doi-asserted-by":"publisher","award":["22XD1425300"],"award-info":[{"award-number":["22XD1425300"]}],"id":[{"id":"10.13039\/501100012242","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010954","name":"Qingdao National Laboratory for Marine Science and Technology","doi-asserted-by":"publisher","award":["No.2022QNLM030003-2"],"award-info":[{"award-number":["No.2022QNLM030003-2"]}],"id":[{"id":"10.13039\/501100010954","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118646","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:14:03Z","timestamp":1770657243000},"page":"118646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Discovery of p300 histone acetyltransferase inhibitors bearing an imidazo[4,5-b]pyridine-2-one scaffold for the treatment of multiple myeloma"],"prefix":"10.1016","volume":"307","author":[{"given":"Ying","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxue","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiongyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinsheng","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5957-6918","authenticated-orcid":false,"given":"Yingxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4733-8255","authenticated-orcid":false,"given":"Zonglong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejmech.2026.118646_bib1","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41580-021-00441-y","article-title":"Modulation of cellular processes by histone and non-histone protein acetylation","volume":"23","author":"Shvedunova","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118646_bib2","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41580-018-0081-3","article-title":"Functions and mechanisms of non-histone protein acetylation","volume":"20","author":"Narita","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118646_bib3","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein lysine acetylation by p300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118646_bib4","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0092-8674(00)82001-2","article-title":"The transcriptional coactivators p300 and CBP are histone acetyltransferases","volume":"87","author":"Ogryzko","year":"1996","journal-title":"Cell"},{"issue":"6610","key":"10.1016\/j.ejmech.2026.118646_bib5","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/384641a0","article-title":"The CBP co-activator is a histone acetyltransferase","volume":"384","author":"Bannister","year":"1996","journal-title":"Nature"},{"issue":"6595","key":"10.1016\/j.ejmech.2026.118646_bib6","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/383099a0","article-title":"Role of CBP\/P300 in nuclear receptor signalling","volume":"383","author":"Chakravarti","year":"1996","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejmech.2026.118646_bib7","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.chembiol.2020.07.002","article-title":"The chemical biology of reversible lysine post-translational modifications","volume":"27","author":"Wang","year":"2020","journal-title":"Cell Chem. Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118646_bib8","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-resolved analysis reveals rapid dynamics and broad scope of the CBP\/p300 acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118646_bib9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/emboj.2010.318","article-title":"Distinct roles of GCN5\/PCAF-mediated H3K9ac and CBP\/p300-mediated H3K18\/27ac in nuclear receptor transactivation","volume":"30","author":"Jin","year":"2011","journal-title":"EMBO J."},{"issue":"24","key":"10.1016\/j.ejmech.2026.118646_bib10","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1038\/sj.onc.1207118","article-title":"p300\/CBP and cancer","volume":"23","author":"Iyer","year":"2004","journal-title":"Oncogene"},{"issue":"11","key":"10.1016\/j.ejmech.2026.118646_bib11","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.7150\/thno.73223","article-title":"Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents","volume":"12","author":"Chen","year":"2022","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.ejmech.2026.118646_bib12","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.118646_bib13","article-title":"Bromodomain inhibition of the transcriptional coactivators CBP\/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma","volume":"5","author":"Conery","year":"2016","journal-title":"eLife"},{"issue":"22","key":"10.1016\/j.ejmech.2026.118646_bib14","first-page":"7638","article-title":"p300 in prostate cancer proliferation and progression","volume":"63","author":"Debes","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118646_bib15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/978-0-387-69080-3_54","article-title":"The role of the transcriptional coactivator p300 in prostate cancer progression","volume":"617","author":"Heemers","year":"2008","journal-title":"Adv. Exp. Med. Biol."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118646_bib16","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118646_bib17","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ng0996-33","article-title":"The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein","volume":"14","author":"Borrow","year":"1996","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118646_bib18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/onc.2015.92","article-title":"The epigenetic regulators CBP and p300 facilitate leukemogenesis and represent therapeutic targets in acute myeloid leukemia","volume":"35","author":"Giotopoulos","year":"2016","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118646_bib19","first-page":"760","article-title":"Expression of p300 and CBP is associated with poor prognosis in small cell lung cancer","volume":"7","author":"Gao","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118646_bib20","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1002\/hep.30544","article-title":"Aberrant super-enhancer landscape in human hepatocellular carcinoma","volume":"69","author":"Tsang","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118646_bib21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.canlet.2011.06.030","article-title":"High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells","volume":"310","author":"Yokomizo","year":"2011","journal-title":"Cancer Lett."},{"issue":"7674","key":"10.1016\/j.ejmech.2026.118646_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.ejmech.2026.118646_bib23","doi-asserted-by":"crossref","first-page":"18606","DOI":"10.1021\/acs.jmedchem.4c01984","article-title":"Discovery of CZL-046 with an (S)-3-Fluoropyrrolidin-2-one scaffold as a p300 bromodomain inhibitor for the treatment of multiple myeloma","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"issue":"22","key":"10.1016\/j.ejmech.2026.118646_bib24","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","article-title":"GNE-781, A highly advanced potent and selective bromodomain inhibitor of cyclic adenosine monophosphate response element binding protein, binding protein (CBP)","volume":"60","author":"Romero","year":"2017","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118646_bib25","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11523-023-00949-7","article-title":"FT-6876, a potent and selective inhibitor of CBP\/p300, is active in preclinical models of androgen receptor-positive breast cancer","volume":"18","author":"Caligiuri","year":"2023","journal-title":"Targeted Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118646_bib26","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1021\/acsmedchemlett.5b00385","article-title":"Characterizing the covalent targets of a small molecule inhibitor of the lysine acetyltransferase P300","volume":"7","author":"Shrimp","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118646_bib27","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","article-title":"Discovery of CPI-1612: a potent, selective, and orally bioavailable EP300\/CBP histone acetyltransferase inhibitor","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118646_bib28","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1021\/acs.jmedchem.2c01641","article-title":"Discovery of DS-9300: a highly potent, selective, and once-daily oral EP300\/CBP histone acetyltransferase inhibitor","volume":"66","author":"Kanada","year":"2023","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118646_bib29","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1021\/acs.jmedchem.9b01721","article-title":"Discovery of highly potent, selective, and orally efficacious p300\/CBP histone acetyltransferases inhibitors","volume":"63","author":"Yang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"21","key":"10.1016\/j.ejmech.2026.118646_bib30","doi-asserted-by":"crossref","first-page":"14391","DOI":"10.1021\/acs.jmedchem.2c00670","article-title":"Discovery of proline-based p300\/CBP inhibitors using DNA-encoded library technology in combination with high-throughput screening","volume":"65","author":"Tian","year":"2022","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.ejmech.2026.118646_bib31","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1093\/emboj\/cdg502","article-title":"Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation","volume":"22","author":"Shikama","year":"2003","journal-title":"EMBO J."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118646_bib32","doi-asserted-by":"crossref","first-page":"916","DOI":"10.14336\/AD.2020.0401","article-title":"p300 in cardiac development and accelerated cardiac aging","volume":"11","author":"Ghosh","year":"2020","journal-title":"Aging Dis"},{"issue":"24","key":"10.1016\/j.ejmech.2026.118646_bib33","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/MCB.05830-11","article-title":"The transcriptional coactivator bp regulates self-renewal and differentiation in adult hematopoietic stem cells","volume":"31","author":"Chan","year":"2011","journal-title":"Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118646_bib34","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0092-8674(00)81165-4","article-title":"Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300","volume":"93","author":"Yao","year":"1998","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.ejmech.2026.118646_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041219","article-title":"The role of CREBBP\/EP300 and its therapeutic implications in hematological malignancies","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:09:14Z","timestamp":1777529354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":35,"alternative-id":["S0223523426000917"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118646","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of p300 histone acetyltransferase inhibitors bearing an imidazo[4,5-b]pyridine-2-one scaffold for the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118646","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118646"}}